The Pharma Data

JANUARY 3, 2021

. This trial is the first to evaluate nasally administered Foralumab to improve the immune system’s fight against coronaviruses. Furthermore, nasal anti-CD3 dampens cytotoxic CD8 T cell responses that are known to cause lung damage in COVID-19 patients.”. About Tiziana Life Sciences. .

Life Science 40

Life Science Clinical Trials Clinical Trials Antibody 40

XTalks

DECEMBER 29, 2023

Tarlatamab is an investigational drug currently undergoing clinical trials to assess its efficacy in patients with two distinct types of neuroendocrine cancer: SCLC and neuroendocrine prostate cancer (NEPC). As a bispecific T-cell engager immunotherapy, tarlatamab directs the patient’s T cells to attack cancer cells exhibiting DLL3.

Clinical Trials 119

Clinical Trials Clinical Trials FDA Approval Trials 119

Drug Discovery World

MARCH 30, 2023

Likang Life Sciences has been granted implied approval by China’s National Medical Products Administration (NMPA) for the clinical trial of its innovative personalised neoantigen-targeted vaccine LK101 Injection for advanced solid tumours.

Regulation 52

Regulation Vaccination Vaccine Trials 52

XTalks

AUGUST 8, 2022

Medicxi is a prominent international life sciences investment firm that invested in over 60 portfolio companies such as Versanis Bio, Rivus Pharmaceuticals, Capella Bioscience and more. One of Medicxi’s portfolio companies called MiroBio is set to be acquired by Gilead Sciences for approximately $405 million in cash.

Immune Response 98

Immune Response Antibody Life Science Engineer 98

Drug Discovery World

JANUARY 31, 2023

Proceeds will support the continued development of the company’s first-of-its-kind immuno-oncology approaches designed to overcome key resistance mechanisms through the creation of novel cancer antigens. This includes the advancement of the company’s lead asset, GRWD5769, into a Phase I/II clinical trial in the first half of 2023. Grey Wolf Therapeutics’ (..)

Immune Response 52

Immune Response Clinical Trials Clinical Trials Life Science 52

XTalks

NOVEMBER 30, 2023

The safety and efficacy of Cabenuva were established through two randomized, open-label, controlled clinical trials involving 1,182 HIV-infected adults who were virologically suppressed (HIV-1 RNA less than 50 copies/mL) before initiating Cabenuva treatment. Additionally, Gag-specific CD8+ T cells demonstrated an increase of 1.7

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

pharmaphorum

MARCH 4, 2021

UK chancellor Rishi Sunak has announced a budget loaded with initiatives designed to kick-start the UK’s economy as it recovers from the coronavirus pandemic, with vaccine development, pharma and life sciences playing a key role. A scheme providing £500 payments to people self-isolating has been extended in England until the summer.

Vaccination 104

Vaccination Vaccine Development Life Science 104

XTalks

SEPTEMBER 21, 2023

announced that the first participant has been dosed in a new Phase I trial for an innovative HIV vaccine candidate, VIR-1388. The trial’s primary objective is to assess the safety of VIR-1388 and its capacity to stimulate a specific immune response against HIV in study participants. Vir Biotechnology, Inc.,

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

Drug Discovery World

FEBRUARY 28, 2024

Using IgE to treat cancer In the UK, a Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working. She has over 25 years’ experience in B2B journalism, ten of those being in life sciences.

Development 64

Development Research Drugs Antibody 64

XTalks

AUGUST 13, 2020

As the rush for a COVID-19 vaccine continues, healthcare services company Kaiser Permanente has joined in on the clinical testing of Pfizer Inc. and BioNTech’s lead vaccine candidate in a Phase III trial being conducted at sites in California and Oregon. Kaiser began Phase III trials of the vaccine at the end of July.

Vaccination 89

Vaccination Vaccine Trials Clinical Trials 89

XTalks

MARCH 19, 2024

These cells are crucial for the body’s immune response, producing antibodies that help fight infection. However, when these cells become cancerous, they proliferate uncontrollably, leading to a myriad of health issues, including bone damage, kidney failure and impaired immune function.

Clinical Trials 59

Clinical Trials Clinical Trials Trials Immune Response 59

The Pharma Data

NOVEMBER 1, 2020

Clinical Data Expected by End of Year. Tiziana Life Sciences plc. (“Tiziana” or the “Company”). This clinical trial will be coordinated by the team at the INTRIALS, a leading, full-service Latin America Clinical Research Organization (CRO), based in Sao Paulo City, Brazil.

Clinical Trials 52

Clinical Trials Clinical Trials Antibody Life Science 52

XTalks

JANUARY 20, 2021

While diseases like celiac are associated with inappropriate activation of the immune system triggered by food antigens, this is not the case in IBS. In a normal, healthy intestine, foods do not trigger immune responses and so in a patient with IBS, something else must activate the response. Mouse and Human Studies.

Immune Response 52

Immune Response Research Allergies Protein 52

pharmaphorum

DECEMBER 15, 2020

million (around $56 million) in a Series B funding round to take its novel group B streptococcus (GBS) vaccine into mid-stage clinical trials. Proceeds will advance the clinical development of MinervaX’s novel GBS vaccine through phase 2 clinical trials, as well as manufacturing and regulatory preparation for phase 3.

Bacteria 52

Bacteria Vaccination Vaccine Immune Response 52

pharmaphorum

AUGUST 27, 2020

The Biotechnology and Biological Sciences Research Council (BBSRC), part of UK Research and Innovation (UKRI), works with universities, research organisations, businesses, charities, and government to develop a supportive ecosystem. The common challenge is undertaking lengthy and capital-intensive phase II/III clinical trials.

Vaccination 120

Vaccination Vaccine Life Science Clinical Trials 120

XTalks

JUNE 15, 2022

Adjuvants can help boost the effectiveness of a vaccine and elicit a stronger immune response. Clinical Trial Results. Results from the PREVENT-19 pediatric expansion trial showed that the vaccine was also effective in adolescents aged 12 to 17 years. NVX-CoV2373 also includes an adjuvant called Matrix-M.

Vaccination 59

Vaccination Vaccine Immune Response Protein 59

XTalks

NOVEMBER 22, 2022

In clinical trials, the treatment delayed stage 3 disease onset for about two years compared with the placebo. Tzield’s FDA approval was based on safety and efficacy data from a randomized, double-blind, event-driven, placebo-controlled trial involving 76 patients with stage 2 type 1 diabetes.

Insulin 97

Insulin Drugs FDA Approval Immune Response 97

XTalks

APRIL 26, 2021

Moreover, a very strong immune response is needed to fend off the disease. The vaccine is protein-based and contains an adjuvant (MM), a component that helps generate a stronger immune response, that was developed by Novavax. Malaria Vaccine Phase II Trial. At six months, 29.5

Vaccination 105

Vaccination Vaccine Immune Response Trials 105

pharmaphorum

JULY 20, 2021

The phase 3 trial being run in support of approval is using a two-shot regimen, with the first dose targeting the original SARS-CoV-2 virus and the second targeting beta (B.1.351) 1.351) variant first identified in South Africa. The post EMA starts review of latecomer GSK/Sanofi COVID-19 vaccine appeared first on.

Vaccination 98

Vaccination Vaccine Protein Immune Response 98

XTalks

NOVEMBER 23, 2020

The global trials are assessing the safety and efficacy of the vaccine in individuals aged 18 years or over from diverse racial and geographic groups who are healthy or have stable underlying medical conditions. Oxford-AstraZeneca COVID-19 Vaccine Induces Immune Responses in Early Clinical Trials.

Vaccination 97

Vaccination Vaccine Clinical Trials Clinical Trials 97

Pharmaceutical Technology

JULY 22, 2022

Peter Hotez’s tweet on PAI Life Sciences’ phase 1 trial of its snail fever vaccine. The phase 1 clinical trial will evaluate the safety and immune response of the vaccine in healthy individuals at the Kaiser Permanente Washington Health Research Institute in Seattle, the article detailed.

Vaccination 130

Vaccination Vaccine Life Science Immune Response 130

XTalks

JULY 28, 2021

While Merck’s previous shot, Pneumovax 23, defends against 23 serotypes and has been on the market for almost four decades, the immune responses it generates are not as durable as Prevnar 13. This is why Pfizer’s Prevnar 13 has dominated the pneumonia vaccine space for more than a decade.

FDA Approval 89

FDA Approval Vaccination Vaccine Immune Response 89

The Pharma Data

JANUARY 3, 2021

Weber is a renowned melanoma specialist and leading immunotherapy translational and clinical scientist. Both will help NexImmune advance current early-stage clinical trials and will guide Company’s translational efforts to develop new immunotherapy products. GAITHERSBURG, Md.,

Immune Response 40

Immune Response Clinical Trials Clinical Trials Development 40

Delveinsight

FEBRUARY 11, 2021

Verily collaborates with Janssen to launch COVID-19 immune response study. Verily is partnering with Johnson & Johnson’s Janssen division to witness the body’s earliest immune responses to a coronavirus infection, with people participating in the research from within their homes. .

Gene Therapy 52

Gene Therapy Gene Immune Response In-Vivo 52

XTalks

JUNE 18, 2021

This is why Regeneron’s announcement of positive clinical trial results that show its antibody cocktail treatment can cut deaths among hospitalized patients is welcome news. It is the first trial to demonstrate that any antibody treatment could improve survival in patients hospitalized with COVID-19.

Antibody 75

Antibody Immune Response Trials Clinical Trials 75

The Pharma Data

DECEMBER 23, 2020

Additionally, Phase 1 clinical data found INO-4800 to have a favorable safety and tolerability profile with no serious adverse events reported; only six Grade 1 adverse events (AEs) were observed, primarily minor injection site reactions. ” Findings from the Phase 1 Clinical Trial. mg and 2.0

DNA 40

DNA Vaccination Vaccine Immune Response 40

XTalks

MAY 30, 2023

Novel treatments: Ongoing research into new treatments for MS include novel immunomodulatory drugs that aim to modulate or suppress the immune response that attacks the myelin sheath in MS. Clinical trials have shown that HSCT can halt disease progression in some people with aggressive forms of MS, although it is a high-risk procedure.

Genetics 98

Genetics Research Immune Response Drugs 98

XTalks

AUGUST 5, 2022

The featured speakers will discuss how to facilitate trial participation in rare disease. Stelara Clinical Trial Results. monoclonal antibody that inhibits interleukin (IL) IL-12 and IL-23 cytokines, which are involved in inflammatory and immune responses. Psoriatic Arthritis Clinical Trial Pipeline.

Clinical Trials 52

Clinical Trials Clinical Trials Antibody Trials 52

pharmaphorum

SEPTEMBER 22, 2022

Le Vert says Osivax’s technology differs, however, as it attacks the virus’ T-cells, making the vaccine more effective in the long term, and that clinical trials have shown promise. The beauty of that T-cell response is that you can actually access the internal parts of the virus,” Le Vert states.

Vaccination 97

Vaccination Vaccine Antibody Clinical Trials 97

XTalks

SEPTEMBER 15, 2020

A vaccine developed by Swedish company Diamyd Medical has demonstrated significant treatment efficacy in a predefined genetic subgroup of individuals with type 1 diabetes in a Phase IIb clinical trial. How the Type 1 Diabetes Vaccine Works. islet cells of the organ, giving rise to the disease. cells of the pancreas.

Vaccination 103

Vaccination Vaccine Insulin Trials 103

XTalks

MAY 1, 2023

XTALKS WEBINAR: Patient-Centricity in Clinical Trials Sites — The Trinity of Patient, Sites and Sponsors Live and On-Demand: Monday, June 12, 2023, at 10am EDT (4pm CEST/EU-Central) Register for this free webinar to learn how the Patient Concierge program increases study participants’ engagement and decreases dropout.

FDA Approval 89

FDA Approval Gene Genetics Protein 89

XTalks

MAY 7, 2021

Novavax published the latest results from a Phase IIb clinical trial conducted in South Africa evaluating the safety and efficacy of NVX-CoV2373, appearing in the NEJM ’s May 6, 2021 issue. 1.351 variant. The results show that the COVID-19 vaccine candidate has an efficacy of 51 percent against the B.1.351

Protein 97

Protein Vaccination Vaccine Trials 97

XTalks

FEBRUARY 27, 2024

Approximately 95 clinical trials evaluating TIL therapies have been registered globally. Amtagvi must be administered at an authorized treatment center (ATC) as part of a treatment regimen that includes lymphodepletion and a short course of high-dose Proleukin (aldesleukin or human recombinant IL-2) to kickstart the immune response.

FDA Approval 52

FDA Approval Manufacturing In-Vivo Trials 52

pharmaphorum

OCTOBER 12, 2022

Similar to how we injected mRNA into people to trigger an immune response and train their immune system against COVID-19, genomic medicine repairs cellular or molecular mechanisms that are dysfunctional and cause disease.”. Debiopharm is interested in innovative therapeutic platforms for tomorrow,” Gibbs says. “We

Genome 104

Genome Genomics Medicine Development 104

XTalks

JULY 8, 2021

Patients with severe COVID-19 often have an overactivation of the immune system, which involves the increased release of cytokines (cytokine release syndrome) such as IL-6. By blocking the cytokine from binding to its receptor, the hyperactive immune response can be tamed. Monoclonal antibodies generally do not come cheap.

Doctors 98

Doctors Doctor Manufacturing Drugs 98

XTalks

JULY 2, 2021

The CDC says that while “clinical trials that study the safety of COVID-19 vaccines and how well they work in pregnant people are underway or planned … based on how these vaccines work in the body, experts believe they are unlikely to pose a risk for people who are pregnant.”.

Vaccination 105

Vaccination Vaccine Protein Immune Response 105

Roots Analysis

DECEMBER 11, 2022

As a result, t-cell immunotherapies market is expected to pick up pace in the coming years adn is anticipated to be the next goldmine in the life sciences industry. Various strategies that are used to redirect T-cells in order to elicit the desired immune response are given below: Source: Roots Analysis.

Marketing 40

Marketing Production Genetics Immune Response 40